key: cord-0304785-dngfjvif authors: Martinez, M.; Nguyen, P.-V.; Su, M.; Cardozo, F.; Valenzuela, A.; Franco, L.; Galeano, M. E.; Rojas, L. E.; Diaz Acosta, C. C.; Fernandez, J.; Ortiz, J.; del Puerto, F.; Mendoza, L.; Nara, E.; Rojas, A.; Waggoner, J. title: SARS-CoV-2 variants in Paraguay: Detection and surveillance with a readily modifiable, multiplex real-time RT-PCR date: 2021-09-20 journal: nan DOI: 10.1101/2021.09.15.21263618 sha: ab2e01db3157dda7a0e2b6f5ca5d37ce5e7606d2 doc_id: 304785 cord_uid: dngfjvif Objectives The objective of the current study was to develop a lower-cost and scalable protocol to identify and monitor SARS-CoV-2 variants in Paraguay by pairing real-time RT-PCR detection of spike mutations with amplicon Sanger sequencing and whole-genome Nanopore sequencing. Methods 201 acute-phase nasopharyngeal samples from SARS-CoV-2-positive individuals were tested with two rRT-PCRs: 1) N2RP assay to confirm SARS-CoV-2 RNA detection (CDC N2 target), and 2) the Spike SNP assay to detect mutations in the spike receptor binding domain. The assay was performed with probes to identify mutations associated with the following variants: alpha (501Y), beta/gamma (417variant/484K/501Y), delta (452R/478K), and lambda (452Q/490S). Results All samples were positive for SARS-CoV-2 in the N2RP assay (mean Ct, 20.8; SD 5.6); 198/201 (98.5%) tested positive in the Spike SNP assay. The most common genotype was 417variant/484K/501Y, detected in 102/198 samples (51.5%) and most consistent with P.1 lineage (gamma variant) in Paraguay. No mutations (K417 only) were found in 64/198 (32.3%); and K417/484K was identified in 22/198 (11.1%), consistent with P.2 (zeta). Seven samples (3.5%) tested positive for 452R without 478K, and one sample with genotype K417/501Y was confirmed as B.1.1.7 (alpha). Results were confirmed by Sanger sequencing in 181/181 samples (100%) with high-quality amplicon sequences, and variant calls were consistent with Nanopore sequencing in 29/29 samples. Conclusions The Spike SNP assay provides accurate detection of mutations associated with SARS-CoV-2 variants. This can be implemented in laboratories performing rRT-PCR to improve population-level surveillance for these mutations and inform the judicious use of scarce sequencing resources. For initial testing, a Spike SNP assay was developed that contained probes for 452Q, 484Q, and was incorporated in the assay in place of 484Q. Addition of the 478K probe had no impact on 1 4 7 452Q or 490S detection (Figure 2 ), and despite overlapping sequences, the 478K and 484Q 1 4 8 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 probes demonstrated no interference when combined in the same reaction ( Figure S1 ). New 1 4 9 probes for 484K and 501Y without LNA bases provided sensitive detection at both sites, though Ct values with the unmodified 484K probe were ~2 cycles later than those generated with the 1 5 1 LNA probe ( Figure S2 ). Testing of clinical samples in the current study was performed with the 1 5 2 original 484K and 501Y probes to maintain consistency with existing protocols. All primers and 1 5 3 probes used in or developed for this study are shown in Table 1 , and their respective locations Clinical samples were collected between November 2020 and April 2021. 113 participants were 1 5 8 female (56.8%, of 199 with gender available), and age and day of symptoms at sample collection 1 5 9 are shown in Table 2 along with N2RP and Spike SNP assay results. The distribution of N2 target Ct values is shown in Figure 3 . The most common genotype identified was Figure 3B ). No differences in patient age or day of symptoms were observed based on genotype (p > 0.05 for all comparisons). All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Characteristic findings for samples with 484K, with and without 501Y, are shown ( Figure 4 ). All Whole genome sequences for 29 samples were obtained using Artic protocol. Ten different 1 8 6 lineages were identified ( was still circulating during 2021, A.2.5.2, was found in one sample with genotype K417/452R. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Among individuals with SARS-CoV-2 infection in Paraguay, the Spike SNP assay provided 1 9 6 accurate detection of targeted mutations in the RBD and, in conjunction with the employed 1 9 7 sequencing protocols, confirmed the predominance of B.1.1.28, P.2 and P.1 in this population For the current study, new probes were generated for mutations that occur within the target 2 0 9 region and are associated with emerging VOCs/VOIs, including delta and lambda variants 2 1 0 ( Figure 1 ). As new designs do not involve separate primer-probe sets, the assay can be readily 2 1 1 modified and reconfigured to include probes that match circulating variants in a particular K417 mutations, avoiding their use in other probes improves access to and reduces costs for 2 1 5 these oligos. An additional benefit to the current design is that up to 4 mutations are targeted in a 2 1 6 single reaction, which has been found to improve variant classification [9] . Other published rRT-2 1 7 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. in single-reaction [12, 15, 17] or multiple-reaction designs [6, 8, 14, 16] , and such protocols may 2 1 9 be more difficult to modify in response to the emergence of new variants. short-read sequencing platforms is less feasible. MinION sequencing has been well described for 2 2 5 SARS-CoV-2 and provides formal confirmation of detected variants, which cannot be achieved 2 2 6 by rRT-PCR alone [4, 5, 25, 31] . Amplicon sequencing provides less information, but as 2 2 7 demonstrated in this study, it serves to confirm Spike SNP calls, differentiate B.1.351 and P.1, 2 2 8 and identify additional mutations in the receptor binding motif. In our study, 4 individuals had 2 2 9 the T478R mutation; the whole genome of two of them were sequenced and were assigned the detected that are not observed in the consensus sequence. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 20, 2021. ; https://doi. org/10.1101 org/10. /2021 The degree of multiplexing possible in the Spike SNP assay is limited by the number of channels 2 4 0 available in common real-time PCR instruments (4-5) as well as the defined 348-base-pair target 2 4 1 region. Based on results of testing for 478K and 484Q in a single reaction, overlapping probes do 2 4 2 not impact performance ( Figure S1 ). However, multiplexed detection of key mutations outside of 2 4 3 the Spike SNP target region would require additional primer-probe sets and assay optimization. A limitation to the current study is the utilization of retrospective convenience samples to 2 4 5 evaluate the testing protocol. Although new data on SARS-CoV-2 variants in Paraguay were 2 4 6 generated, we cannot calculate variant prevalence from these data. In conclusion, the Spike SNP assay provides accurate detection of mutations that are associated with VOCs/VOIs in Paraguay. This can be implemented in SARS-CoV-2 testing protocols to sequencing, which provides additional information. The assay can be implemented in any 2 5 2 laboratory performing rRT-PCR to improve surveillance for these mutations and inform the 2 5 3 judicious use of scarce sequencing resources. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The authors thank the staff at the Instituto de Investigaciones en Ciencias de la Salud, Goertzen (Hospital Loma Plata) for their support during the study period and the COVID 2 6 0 pandemic in Paraguay. We also thank members of the Variant Task Force at Emory University, Authors declare that they have no conflict of interest. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 501Y d 5'-HEX-CCCAC+T+T+ATGGTGTTGG-3IABkFQ-3' 200 Unmodified Probes 452R d 5'-CFR610-ATAATTACCGGTATAGATTGTTTAGGAAGT-BHQ-2-3 501Y 5'-CFO560-CAACCCACTTATGGTGTTGGTTAC-BHQ-1-3' 200 452Q 5'-CFR610-ATAATTACCAGTATAGATTGTTTAGGAAGT-BHQ-2-3' 200 490S 5'-FAM-ACTCTCCTTTACAATCATATGGTTTCC-BHQ-1-3' 200 478K 5'-CFO560-CGGTAGCAAACCTTGTAATGGTG-BHQ-1-3' 200 qPCR assay for SARS-CoV-2 variants of concern (Alpha, B.1.1.7 and Beta, B.1.351) detection and 3 3 5 quantification in wastewater, Environ Res 201 (2021) 111653. 3 3 6 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Michel, A. Nitsche, AmpliCoV: Rapid Whole-Genome Sequencing Using Multiplex PCR Amplification 3 5 8 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CoV-2, Front Microbiol 12 (2021) preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. above the graph. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. shown for reference (blue curves). All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.15.21263618 doi: medRxiv preprint Table 2 . Genotypes detected in the Spike SNP assay, patient demographics and the percent